netFormulary
 Report : Medicines with links to NICE 14/11/2018 09:34:38

[Back]

Report looks at the links table and pulls back all the items in the formulary where there is a link with 'nice.org' in the URL

You can sort this table Medicines Link Name or Link URL by clicking on the title

Selecting the Medicine name will take you to the entry in the formulary, Selecting the Link name will follow the link

 
Medicines/Item Section Status Link Name / Link URL
Dupilumab injection 13.05.03 Formulary NICE TA534: Dupilumab for treating moderate to severe atopic dermatitis
Abatacept injection 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Abatacept injection 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Abiraterone tabs 08.03.04.02 Formulary NICE TA259: Abiraterone for castration-resistant metastatic prostate cancer previously treated with a docetaxel-containing regimen
Abiraterone tabs 08.03.04.02 Formulary NICE TA387: Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Adalimumab injection 13.05.03 Formulary NICE TA146: Adalimumab for the treatment of adults with psoriasis
Adalimumab injection 13.05.03 Formulary NICE TA392: Adalimumab for treating moderate to severe hidradenitis suppurativa
Adalimumab injection 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Adalimumab injection 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Adalimumab injection 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Adalimumab injection 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Adalimumab injection 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Adalimumab injection 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Adalimumab injection 10.01.03 Formulary NICE TA199: Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis
Adalimumab injection 11.99.99.99 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Adefovir dipivoxil tablets 05.03.03.01 Formulary NICE TA96: Hepatitis B (chronic) - adefovir dipivoxil and pegylated interferon alpha-2a
Adefovir dipivoxil tablets 05.03.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA96
Afatinib tabs 08.01.05 Formulary NICE TA310: Afatinib for treating epidermal growth factor receptor mutation-positive locally advanced or metastatic non-small-cell lung cancer
Aflibercept 08.01.05 Non Formulary NICE TA307: Aflibercept in combination with irinotecan and fluorouracil-based therapy for treating metastatic colorectal cancer that has progressed following prior oxaliplatin-based chemotherapy
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA305: Aflibercept for treating visual impairment caused by macular oedema secondary to central retinal vein occlusion
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA409: Aflibercept for treating visual impairment caused by macular oedema after branch retinal vein occlusion
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA294: Macular degeneration (wet age-related) - aflibercept
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA486: Aflibercept for treating choroidal neovascularisation
Aflibercept intravitreal injection 11.08.02 Formulary NICE TA346: Aflibercept for treating diabetic macular oedema
Alectinib caps 08.01.05 Formulary NICE TA536: Alectinib for untreated ALK-positive advanced non-small-cell lung cancer
Alemtuzumab 08.02.03 Non Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alemtuzumab injection 08.02.03 Formulary NICE TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis
Alirocumab injection 02.12 Restricted Use NICE TA393: Alirocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Alitretinoin caps 13.05.01 Formulary NICE TA177: Eczema (chronic) - alitretinoin
Alteplase injection 02.10.02 Formulary NICE TA264: Ischaemic stroke (acute) - alteplase
Amantadine 04.09.01 Non Formulary Amantadine, oseltamivir and zanamivir for the treatment of influenza
Amantadine caps, syrup 04.09.01 Formulary NICE CG186: Multiple sclerosis in adults: management
Anti-D (Rh0) Immunoglobulin injection 14.05.03 Formulary NICE TA156: Anti-D in pregnant women
Apixaban tabs 02.08.02 Formulary NICE TA275: Stroke and systemic embolism (prevention, non-valvular atrial fibrillation) - apixaban
Apixaban tabs 02.08.02 Formulary NICE TA245: Venous thromboembolism - apixaban (hip and knee surgery
Apixaban tabs 02.08.02 Formulary NICE TA341: Apixaban for treatment and secondary prevention of DVT and/or PE
Apremilast tabs 13.05.03 Formulary NICE TA419: Apremilast for treating moderate to severe plaque psoriasis
Apremilast tabs 13.05.03 Formulary NICE TA433: Apremilast for treating active psoriatic arthritis
Aripiprazole tabs 04.02.01 Restricted Use NICE TA213: Aripiprazole for the treatment of schizophrenia in people aged 15 -17 years
Aripiprazole tabs 04.02.01 Restricted Use NICE TA292: Aripiprazole for treating moderate to severe manic episodes in adolescents with bipolar I disorder
Arsenic trioxide injection 08.01.05 Formulary NICE TA526: Arsenic trioxide for treating acute promyelocytic leukaemia
Atezolizumab injection 08.01.05 Formulary NICE TA520: Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapy
Atezolizumab injection 08.01.05 Formulary NICE TA492: Atezolizumab for untreated locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Atezolizumab injection 08.01.05 Formulary NICE TA525: Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Avelumab injection 08.01.05 Formulary NICE TA517: Avelumab for treating metastatic Merkel cell carcinoma
Axitinib tabs 08.01.05 Formulary NICE TA333: Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment
Azacitidine injection 08.01.03 Restricted Use NICE TA218: Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia
Baricitinib tabs 10.01.03 Formulary NICE TA466: Baricitinib for moderate to severe rheumatoid arthritis
Basiliximab injection 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Basiliximab injection 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Bee and wasp allergen extracts 03.04.02 Restricted Use NICE TA246: Pharmalgen for the treatment of bee and wasp venom allergy
Belimumab injection 10.01.03 Restricted Use NICE TA397: Belimumab for treating active autoantibody-positive systemic lupus erythematosus
Bendamustine injection 08.01.01 Formulary NICE TA216: Bendamustine for the first-line treatment of chronic lymphocytic leukaemia
Bivalirudin injection 02.08.01 Formulary NICE CG94: Unstable angina and NSTEMI
Bivalirudin injection 02.08.01 Formulary NICE TA230 : Bivalirudin for the treatment of STEMI, 2011
Blinatumomab injection 08.02.03 Formulary NICE TA450: Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia
Bortezomib injection 08.01.05 Formulary NICE TA370: Bortezomib for previously untreated mantle cell lymphoma
Bortezomib injection 08.01.05 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Bortezomib injection 08.01.05 Formulary NICE TA129: Bortezomib monotherapy for relapsed multiple myeloma
Bortezomib injection 08.01.05 Formulary NICE TA311: Bortezomib for induction therapy in multiple myeloma before high-dose chemotherapy and autologous stem cell transplantation
Bosutinib tabs 08.01.05 Formulary NICE TA401: Bosutinib for previously treated chronic myeloid leukaemia
Botulinum Toxin Type A 04.07.04.02 Restricted Use NICE TA260: Botox for migraine prophylaxis
Brentuximab injection 08.01.05 Formulary NICE TA524: Brentuximab vedotin for treating CD30-positive Hodgkin lymphoma
Brentuximab injection 08.01.05 Formulary NICE TA478: Brentuximab vedotin for treating relapsed or refractory systemic anaplastic large cell lymphoma
Brodalumab injection 13.05.03 Formulary NICE TA511: Brodalumab for treating moderate to severe plaque psoriasis
Cabazitaxel injection 08.01.05 Formulary NICE TA391: Cabazitaxel for hormone-relapsed metastatic prostate cancer treated with docetaxel
Cabozantinib caps 08.01.05 Formulary NICE TA516: Cabozantinib for treating medullary thyroid cancer
Cabozantinib tablets 08.01.05 Formulary NICE TA463: Cabozantinib for previously treated advanced renal cell carcinoma
Cabozantinib tablets 08.01.05 Formulary NICE TA542: Cabozantinib for untreated advanced renal cell carcinoma
Canagliflozin tabs 06.01.02.03 Formulary NICE TA315: Canagliflozin in combination therapy for treating type 2 diabetes
Canagliflozin tabs 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Capecitabine tabs 08.01.03 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Capecitabine tabs 08.01.03 Formulary NICE TA61: Guidance on the use of capecitabine and tegafur with uracil for metastatic colorectal cancer
Capecitabine tabs 08.01.03 Formulary NICE CG81: Advanced breast cancer: diagnosis and treatment
Capecitabine tabs 08.01.03 Formulary NICE TA191: Capecitabine for the treatment of advanced gastric cancer
Carboplatin injection 08.01.05 Formulary NICE CG121: Lung cancer: diagnosis and management
Carfilzomib injection 08.01.05 Formulary NICE TA457: Carfilzomib for previously treated multiple myeloma
Carmustine 08.01.01 Non Formulary NICE TA121: Glioma (newly diagnosed and high grade) - carmustine implants and temozolomide
Carmustine implant 08.01.01 Formulary NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Ceritinib caps 08.01.05 Formulary NICE TA395: Ceritinib for previously treated anaplastic lymphoma kinase positive non-small-cell lung cancer
Ceritinib caps 08.01.05 Formulary NICE TA500: Ceritinib for untreated ALK-positive non-small-cell lung cancer
Certolizumab pegol injection 10.01.03 Formulary NICE TA415: Certolizumab pegol for treating rheumatoid arthritis after inadequate response to a TNF-alpha inhibitor
Certolizumab pegol injection 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Certolizumab pegol injection 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Certolizumab pegol injection 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Cetuximab injection 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Cetuximab injection 08.01.05 Formulary NICE TA473: Cetuximab for treating recurrent or metastatic squamous cell cancer of the head and neck
Cetuximab injection 08.01.05 Formulary NICE TA145: Cetuximab for the treatment of locally advanced squamous cell cancer of the head and neck
Ciclosporin 0.1% eye drops 11.04.02 Restricted Use NICE TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
Cinacalcet tablets 09.05.01.02 Restricted Use NICE TA117: Cinacalcet for the treatment of secondary hyperparathyroidism in patients with end-stage renal disease on maintenance dialysis therapy
Cisplatin injection 08.01.05 Formulary NICE CG121: Lung cancer: diagnosis and management
Cladribine tabs 08.02.04 Formulary NICE TA493: Cladribine tablets for treating relapsing–remitting multiple sclerosis
Clomipramine caps 04.03.01 Restricted Use NICE CG113: Generalised anxiety disorder and panic disorder in adults: management
Colistimethate sodium dry powder for inhalation 05.01.07 Formulary NICE TA276: Cystic fibrosis (pseudomonas lung infection) - colistimethate sodium and tobramycin
Collagenase injection 10.03.01 Restricted Use NICE TA459: Collagenase clostridium histolyticum for treating Dupuytren’s contracture
Crizotinib caps 08.01.05 Formulary NICE TA406: Crizotinib for untreated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib caps 08.01.05 Formulary NICE TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer
Crizotinib caps 08.01.05 Formulary NICE TA529: Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer
Cubitan A2.03.02 Non Formulary NICE TA242: Colorectal cancer (metastatic) 2nd line - cetuximab, bevacizumab and panitumumab (review)
Dabigatran caps 02.08.02 Formulary NICE TA249: Dabigatran for Stroke prevention in AF
Dabigatran caps 02.08.02 Formulary NICE TA327: Dabigatran for treatment and secondary prevention of DVT and/or PE
Dabigatran caps 02.08.02 Formulary NICE TA157: Venous thromboembolism - dabigatran
Dabrafenib caps 08.01.05 Formulary NICE TA321: Dabrafenib for treating unresectable or metastatic BRAF V600 mutation‑positive melanoma
Daclatasvir tabs 05.03.03.02 Formulary NICE TA364: Daclatasvir for treating chronic hepatitis C
Daclizumab injection 08.02.04 Formulary NICE TA441: Daclizumab for treating relapsing–remitting multiple sclerosis
Dapagliflozin tabs 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Dapagliflozin tabs 06.01.02.03 Formulary NICE TA288: Dapagliflozin in combination therapy for treating type 2 diabetes
Dapagliflozin tabs 06.01.02.03 Formulary NICE TA418: Dapagliflozin in triple therapy for treating type 2 diabetes
Daratumumab injection 08.02.04 Formulary NICE TA510: Daratumumab monotherapy for treating relapsed and refractory multiple myeloma
Dasatinib tabs 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Dasatinib tabs 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Decitabine 08.01.03 Non Formulary NICE TA270: Leukaemia (acute myeloid ) - decitabine (terminated appraisal) (TA270)
Degarelix injection 08.03.04.02 Formulary NICE TA404: Degarelix for treating advanced hormone-dependent prostate cancer
Denosumab 06.06.02 Formulary NICE TA265: Bone metastases from solid tumours - denosumab
Denosumab 06.06.02 Formulary NICE TA204: Osteoporotic fractures - denosumab
Dexamethasone intravitreal implant 11.08.02 Formulary NICE TA349: Dexamethasone intravitreal implant for treating diabetic macular oedema
Dexamethasone intravitreal implant 11.08.02 Formulary NICE TA460: Adalimumab and dexamethasone for treating non-infectious uveitis
Dexamethasone intravitreal implant 11.08.02 Formulary NICE TA229: Dexamethasone intravitreal implant for the treatment of macular oedema
Dimethyl fumarate caps 08.02.04 Formulary NICE TA320: Dimethyl fumarate for treating relapsing‑remitting multiple sclerosis
Dimethyl fumarate tablets 13.05.03 Formulary NICE TA475: Dimethyl fumarate for treating moderate to severe plaque psoriasis
Dinoprostone vaginal gel, pessaries 07.01.01 Formulary NICE CG70: Inducing labour
Docetaxel injection 08.01.05 Formulary NICE TA109: Docetaxel for the adjuvant treatment of early node-positive breast cancer
Docetaxel injection 08.01.05 Formulary NICE TA101: Docetaxel for the treatment of hormone-refractory metastatic prostate cancer
Docetaxel injection 08.01.05 Formulary NICE CG81: Advanced breast cancer: diagnosis and treatment
Docetaxel injection 08.01.05 Formulary NICE CG121: Lung cancer: diagnosis and management
Doxorubicin hydrochloride pegylated liposomal injection 08.01.02 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Dronedarone tabs 02.03.02 Formulary NICE TA197: Atrial fibrillation - dronedarone
Eculizumab injection 09.01.03 Formulary NICE HST1: Eculizumab for treating atypical haemolytic uraemic syndrome
Edoxaban tabs 02.08.02 Formulary NICE TA354: Edoxaban for treating and for preventing DVT and/or PE
Edoxaban tabs 02.08.02 Formulary NICE TA355: Edoxaban for thromboprohylaxis in non-valvular AF
Eltrombopag tablets 09.01.04 Restricted Use NICE TA293: Eltrombopag for treating chronic immune (idiopathic) thrombocytopenic purpura (review of technology appraisal 205)
Eluxadoline tablets 01.05 Formulary NICE TA471: Eluxadoline for treating irritable bowel syndrome with diarrhoea
Empagliflozin tabs 06.01.02.03 Formulary NICE TA390: Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes
Empagliflozin tabs 06.01.02.03 Formulary NICE TA336: Empagliflozin in combination therapy for treating type 2 diabetes
Entecavir tabs, oral solution 05.03.03.01 Formulary NICE CG165: Hepatitis B (incorporates TA153)
Entecavir tabs, oral solution 05.03.03.01 Formulary NICE TA153: Hepatitis B (chronic) - etecavir
Enzalutamide caps 08.03.04.02 Formulary NICE TA377: Enzalutamide for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated
Enzalutamide caps 08.03.04.02 Formulary NICE TA316: Enzalutamide for metastatic hormone‑relapsed prostate cancer previously treated with a docetaxel‑containing regimen
Epclusa® tabs 05.03.03.02 Formulary NICE TA430: Sofosbuvir–velpatasvir for treating chronic hepatitis C
Eplerenone tabs 02.02.03 Formulary NICE CG172 Myocardial Infarction: cardiac rehabilitation and secondary prevention
Eplerenone tabs 02.02.03 Formulary NICE NG106: Chronic heart failure in adults: diagnosis and management
Eribulin injection 08.01.05 Formulary NICE TA423: Eribulin for treating locally advanced or metastatic breast cancer after 2 or more chemotherapy regimens
Erlotinib tabs 08.01.05 Formulary NICE TA258: Erlotinib for the first-line treatment of locally advanced or metastatic EGFR-TK mutation-positive non-small-cell lung cancer
Erlotinib tabs 08.01.05 Formulary NICE TA374: Erlotinib and gefitinib for treating non-small-cell lung cancer that has progressed after prior chemotherapy
Etanercept 13.05.03 Non Formulary NICE TA103: Psoriasis - efalizumab and etanercept
Etanercept injection 13.05.03 Formulary NICE TA103: Etanercept and efalizumab for the treatment of adults with psoriasis
Etanercept injection 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Etanercept injection 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Etanercept injection 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Etanercept injection 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Etanercept injection 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Etelcalcetide injection 09.05.01.02 Formulary NICE TA448: Etelcalcetide for treating secondary hyperparathyroidism
Everolimus 08.01.05 Non Formulary NICE TA219: Everolimus for second-line treatment of renal cell cancer
Everolimus tabs 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Everolimus tabs 08.01.05 Formulary NICE TA432: Everolimus for advanced renal cell carcinoma after previous treatment
Everolimus tabs 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Everolimus tabs 08.01.05 Formulary NICE TA421: Everolimus with exemestane for treating advanced breast cancer after endocrine therapy
Evolocumab injection 02.12 Restricted Use NICE TA394: Evolocumab for treating primary hypercholesterolaemia and mixed dyslipidaemia
Ezetimibe tabs 02.12 Formulary NICE TA385:Ezetimibe for primary heterozygous-familial and non-familial hypercholesterolaemia
Febuxostat tabs 10.01.04 Formulary NICE TA164: Hyperuricaemia - febuxostat
Finasteride tabs 06.04.02 Formulary NICE CG97: Lower urinary tract symptoms
Fingolimod caps 08.02.04 Formulary NICE TA254: Fingolimod for highly active relapsing remitting multiple sclerosis
Fludarabine tabs, injection 08.01.03 Formulary NICE TA29: Guidance on the use of fludarabine for B-cell chronic lymphocytic leukaemia
Fluocinolone intravitreal implant 11.08.02 Formulary NICE TA301: Fluocinolone acetonide intravitreal implant for treating chronic diabetic macular oedema after an inadequate response to prior therapy (rapid review of technology appraisal guidance 271)
Fulvestrant 08.03.04.01 Non Formulary NICE TA239: Fulvestrant for the treatment of locally advanced or metastatic breast cancer
Gefitinib tabs 08.01.05 Formulary NICE TA192: Gefitinib for the first-line treatment of locally advanced or metastatic non-small-cell lung cancer
Gemcitabine injection 08.01.03 Formulary NICE TA25:Guidance on the use of gemcitabine for the treatment of pancreatic cancer
Gemcitabine injection 08.01.03 Formulary NICE CG121: Lung cancer: diagnosis and management
Gemcitabine injection 08.01.03 Formulary NICE TA116: Gemcitabine for the treatment of metastatic breast cancer
Glatiramer acetate injection 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Glatiramer acetate injection 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Golimumab injection 10.01.03 Formulary NICE TA220: Psoriatic arthritis - golimumab
Golimumab injection 10.01.03 Formulary NICE TA225: Rheumatoid arthritis - golimumab
Golimumab injection 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Golimumab injection 10.01.03 Formulary NICE TA497: Golimumab for treating non-radiographic axial spondyloarthritis
Golimumab injection 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Golimumab injection 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Guselkumab injection 13.05.03 Formulary NICE TA521: Guselkumab for treating moderate to severe plaque psoriasis
Harvoni® tabs 05.03.03.02 Formulary NICE TA363: Ledipasvir–sofosbuvir for treating chronic hepatitis C
Holoclar 11.99.99.99 Formulary NICE TA467: Holoclar for treating limbal stem cell deficiency after eye burns
Ibrutinib caps 08.01.05 Formulary NICE TA491: Ibrutinib for treating Waldenstrom’s macroglobulinaemia
Ibrutinib caps 08.01.05 Formulary NICE TA502: Ibrutinib for treating relapsed or refractory mantle cell lymphoma
Ibrutinib caps 08.01.05 Formulary NICE TA429: Ibrutinib for previously treated chronic lymphocytic leukaemia and untreated chronic lymphocytic leukaemia with 17p deletion or TP53 mutation
Idelalisib tabs 08.01.05 Formulary NICE TA359: Idelalisib for treating chronic lymphocytic leukaemia
Imatinib tabs 08.01.05 Formulary NICE TA70: Guidance on the use of imatinib for chronic myeloid leukaemia
Imatinib tabs 08.01.05 Formulary NICE TA86: Imatinib for the treatment of unresectable and/or metastatic gastro-intestinal stromal tumours
Imatinib tabs 08.01.05 Formulary NICE TA326: Imatinib for the adjuvant treatment of gastrointestinal stromal tumours
Imatinib tabs 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Imipramine tabs 04.03.01 Formulary NICE CG113: Generalised anxiety disorder and panic disorder in adults: management
Infliximab injection 01.05.03 Formulary NICE TA329: Infliximab, adalimumab and golimumab for treating moderately to severely active ulcerative colitis after the failure of conventional therapy
Infliximab injection 01.05.03 Formulary NICE TA163 Infliximab for acute exacerbations of ulcerative colitis
Infliximab injection 01.05.03 Formulary NICE TA187: Infliximab and adalimumab for the treatment of Crohn’s disease
Infliximab injection 13.05.03 Formulary NICE TA134: Infliximab for the treatment of adults with psoriasis
Infliximab injection 10.01.03 Formulary NICE TA199: Psoriatic arthritis - etanercept, infliximab and adalimumab
Infliximab injection 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Infliximab injection 10.01.03 Formulary NICE TA383: TNF-alpha inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis
Infliximab injection 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Inotuzumab ozogamicin injection 08.01.05 Formulary NICE TA541: Inotuzumab ozogamicin for treating relapsed or refractory B-cell acute lymphoblastic leukaemia
Interferon beta-1a injection 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta-1a injection 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Interferon beta-1b injection 08.02.04 Formulary NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
Ipilimumab injection 08.01.05 Formulary NICE TA268: Ipilimumab for previously treated advanced (unresectable or metastatic) melanoma
Ipilimumab injection 08.01.05 Formulary NICE TA319: Ipilimumab for previously untreated advanced (unresectable or metastatic) melanoma
Ipilimumab injection 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Irinotecan Hydrochloride injection 08.01.05 Formulary NICE CG131: Colorectal cancer: diagnosis and management
Ivabradine 02.06.03 Non Formulary NICE TA267: Chronic heart failure - ivabradine
Ivabradine 02.06.03 Non Formulary NICE CG126: Guidance on Stable Angina
Ivabradine tabs 02.06.03 Restricted Use NICE TA267: Ivabradine for treating chronic heart failure
Ixazomib caps 08.02.04 Formulary NICE TA505: Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma
Ixekizumab injection 13.05.03 Formulary NICE TA442: Ixekizumab for treating moderate to severe plaque psoriasis
Lamivudine tabs, oral solution 05.03.03.01 Formulary NICE CG165: Hepatitis B
Lapatinib 08.01.05 Non Formulary NICE TA257: in combination with an aromatase inhibitor for HER2 positive metastatic breast cancer
Lenalidomide caps 08.02.04 Formulary NICE TA322: Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Lenalidomide caps 08.02.04 Formulary NICE TA171: Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy
Lenvatinib caps 08.01.05 Formulary NICE TA498: Lenvatinib with everolimus for previously treated advanced renal cell carcinoma
Lenvatinib injection 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Levonorgestrel intrauterine system 52 mg 07.03.02.03 Formulary NICE NG88: Heavy menstrual bleeding: assessment and management
Lubiprostone capsules 01.06.07 Formulary NICE TA318: Lubiprostone for treating chronic idiopathic constipation
Lutetium (177Lu) oxodotreotide injection 08.01.05 Formulary NICE TA539: Lutetium (177Lu) oxodotreotide for treating unresectable or metastatic neuroendocrine tumours
Mannitol inhalation powder 03.07 Formulary NICE TA266 Cystic fibrosis - mannitol dry powder for inhalation (TA266)
Maviret® tabs 05.03.03.02 Formulary NICE TA99: Glecaprevir–pibrentasvir for treating chronic hepatitis C
Mepolizumab injection 03.04.02 Formulary NICE TA431: Mepolizumab for treating severe refractory eosinophilic asthma
Metformin tabs 06.01.02.02 Formulary NICE NG3: Diabetes in pregnancy: management from preconception to the postnatal period
Midostaurin caps 08.01.05 Formulary NICE TA523: Midostaurin for untreated acute myeloid leukaemia
Mifamurtide 08.02.04 Non Formulary NICE TA154: Hepatitis B - telbivudine
Mifamurtide injection 08.02.04 Formulary NICE TA235: Mifamurtide for the treatment of osteosarcoma
Mirabegron tabs 07.04.02 Restricted Use NICE TA290: Mirabegron for overactive bladder
Misoprostol tabs 07.01.01 Formulary NICE CG154: Ectopic pregnancy and miscarriage: diagnosis and initial management
Mycophenolate Mofetil tabs, caps, suspension, injection 08.02.01 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Mycophenolate Mofetil tabs, caps, suspension, injection 08.02.01 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Naftidrofuryl caps 02.06.04 Formulary NICE TA223: Cilostazol, naftidrofuryl oxalate, pentoxifylline and inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial disease
Nalmefene tabs 04.10.01 Restricted Use NICE TA325: Nalmefene for reducing alcohol consumption in people with alcohol dependence
Naloxegol tabs 01.06.06 Formulary NICE TA345 Naloxegol for treating opioid‑induced constipation
Naltrexone tabs 04.10.03 Formulary NICE TA115: Naltrexone for the management of opioid dependence
Naltrexone–bupropion m/r tabs 04.05.02 Non Formulary NICE TA494: Naltrexone–bupropion for managing overweight and obesity
Natalizumab injection 08.02.04 Restricted Use NICE TA127: Natalizumab for the treatment of adults with highly active relapsing–remitting multiple sclerosis
Nilotinib caps 08.01.05 Formulary NICE TA426: Dasatinib, nilotinib and imatinib for untreated chronic myeloid leukaemia
Nilotinib caps 08.01.05 Formulary NICE TA425: Dasatinib, nilotinib and high-dose imatinib for treating imatinib-resistant or intolerant chronic myeloid leukaemia
Nintedanib caps 08.01 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Nintedanib caps 08.01.05 Formulary NICE TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
Nintedanib caps 03.11 Formulary NICE TA379: Nintedanib for treating idiopathic pulmonary fibrosis
Niraparib caps 08.01.05 Formulary NICE TA528: Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer
Nivolumab injection 08.01.05 Formulary NICE TA530: Nivolumab for treating locally advanced unresectable or metastatic urothelial cancer after platinum-containing chemotherapy
Nivolumab injection 08.01.05 Formulary NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Nivolumab injection 08.01.05 Formulary NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Nivolumab injection 08.01.05 Formulary NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Nivolumab injection 08.01.05 Formulary NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Nivolumab injection 08.01.05 Formulary NICE TA462: Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Nivolumab injection 08.01.05 Formulary NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Nivolumab injection 08.01.05 Formulary NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Obeticholic acid tabs 01.09.01 Formulary NICE TA443: Obeticholic acid for treating primary biliary cholangitis
Obinutuzumab injection 08.02.03 Formulary NICE TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
Obinutuzumab injection 08.02.03 Formulary NICE TA472: Obinutuzumab with bendamustine for treating follicular lymphoma refractory to rituximab
Obinutuzumab injection 08.02.03 Formulary NICE TA513: Obinutuzumab for untreated advanced follicular lymphoma
Ocrelizumab injection 08.02.04 Formulary NICE TA 533: Ocrelizumab for treating relapsing–remitting multiple sclerosis
Ocriplasmin intravitreal injection 11.08.02 Formulary NICE TA297: Ocriplasmin for treating vitreomacular traction
Ofatumumab injection 08.02.03 Formulary NICE TA344: Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia
Olaparib caps, tabs 08.01.05 Formulary NICE TA381: Olaparib for relapsed, platinum-sensitive, BRCA positive ovarian, fallopian tube and peritoneal cancer after response to second-line or subsequent platinum-based chemotherapy
Olaratumab injection 08.01.05 Formulary NICE TA465: Olaratumab in combination with doxorubicin for treating advanced soft tissue sarcoma
Omalizumab injection 03.04.02 Restricted Use NICE TA339: Omalizumab for previously treated chronic spontaneous urticaria
Omalizumab injection 03.04.02 Restricted Use NICE TA278: Asthma (severe, persistent, patients aged 6+, adults) - omalizumab (rev TA133, TA201)
Orlistat caps 04.05.01 Formulary NICE CG189: Obesity: identification, assessment and management
Osimertinib tabs 08.01.05 Formulary NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Oxaliplatin injection 08.01.05 Formulary NICE TA100: Capecitabine and oxaliplatin in the adjuvant treatment of stage III (Dukes’ C) colon cancer
Oxaliplatin injection 08.01.05 Formulary NICE CG131: Colorectal cancer: diagnosis and management
Oxytocin injection 07.01.01 Formulary NICE CG70: Inducing labour
Paclitaxel albumin injection 08.01.05 Formulary NICE TA476: Paclitaxel as albumin-bound nanoparticles with gemcitabine for untreated metastatic pancreatic cancer
Paclitaxel injection 08.01.05 Formulary NICE CG81: Advanced breast cancer: diagnosis and treatment
Paclitaxel injection 08.01.05 Formulary NICE TA389: Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for treating recurrent ovarian cancer
Paclitaxel injection 08.01.05 Formulary NICE CG121: Lung cancer: diagnosis and management
Paclitaxel injection 08.01.05 Formulary NICE TA55: Guidance on the use of paclitaxel in the treatment of ovarian cancer
Palbociclib tabs 08.01.05 Formulary NICE TA495: Palbociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Panitumumab injection 08.01.05 Formulary NICE TA439: Cetuximab and panitumumab for previously untreated metastatic colorectal cancer
Panobinostat caps 08.01.05 Formulary NICE TA380: Panobinostat for treating multiple myeloma after at least 2 previous treatments
Pazopanib tabs 08.01.05 Formulary NICE TA215: Pazopanib for the first-line treatment of advanced renal cell carcinoma
Pegaptanib Sodium 11.08.02 Non Formulary NICE TA155: guidance on pegaptanib in AMD (August 2008)
Pegaspargase injection 08.01.05 Formulary NICE TA408: Pegaspargase for treating acute lymphoblastic leukaemia
Peginterferon Alfa 08.02.04 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Peginterferon Alfa 08.02.04 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Peginterferon alfa-2a injection 05.03.03.01 Formulary NICE TA96: Adefovir and peginterferon alfa-2a for the treatment of chronic hepatitis B
Peginterferon alfa-2a injection 05.03.03.02 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon alfa-2a injection 05.03.03.02 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Peginterferon alfa-2a injection 05.03.03.02 Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon alfa-2b injection 05.03.03.02 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Peginterferon alfa-2b injection 05.03.03.02 Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Peginterferon alfa-2b injection 05.03.03.02 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Pegylated liposomal irinotecan injection 08.01.05 Non Formulary NICE TA440: Pegylated liposomal irinotecan for treating pancreatic cancer after gemcitabine
Pembrolizumab injection 08.01.05 Formulary NICE TA540: Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma
Pembrolizumab injection 08.01.05 Formulary NICE TA447: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab injection 08.01.05 Formulary NICE TA531: Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancer
Pembrolizumab injection 08.01.05 Formulary NICE TA428: Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapy
Pembrolizumab injection 08.01.05 Formulary NICE TA519: Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy
Pembrolizumab injection 08.01.05 Formulary NICE TA522: Pembrolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable
Pembrolizumab injection 08.01.05 Formulary NICE TA357: Pembrolizumab for treating advanced melanoma after disease progression with ipilimumab
Pembrolizumab injection 08.01.05 Formulary NICE TA366: Pembrolizumab for advanced melanoma not previously treated with ipilimumab
Pemetrexed injection 08.01.03 Formulary NICE TA190: Pemetrexed for the maintenance treatment of non-small-cell lung cancer
Pemetrexed injection 08.01.03 Formulary NICE TA135: Pemetrexed for the treatment of malignant pleural mesothelioma
Pemetrexed injection 08.01.03 Formulary NICE TA181: Pemetrexed for the first-line treatment of non-small-cell lung cancer
Pemetrexed injection 08.01.03 Formulary NICE TA402: Pemetrexed maintenance treatment for non-squamous non-small-cell lung cancer after pemetrexed and cisplatin
Pepto-Bismol chewable tabs 01.01 Formulary NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
Pertuzumab injection 08.01.05 Formulary NICE TA509: Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer
Pertuzumab injection 08.01.05 Formulary NICE TA424: Pertuzumab for the neoadjuvant treatment of HER2-positive breast cancer
Pimecrolimus cream 1% 13.05.03 Formulary NICE TA82: Pimecrolimus and tacrolimus for atopic dermatitis (eczema)
Pirfenidone caps 03.11 Formulary NICE TA5004: Pirfenidone for treating idiopathic pulmonary fibrosis
Pixantrone injection 08.01.02 Formulary NICE TA306: Pixantrone monotherapy for treating multiply relapsed or refractory aggressive non-Hodgkin’s B‑cell lymphoma
Pomalidomide caps 08.02.04 Formulary NICE TA427: Pomalidomide for multiple myeloma previously treated with lenalidomide and bortezomib
Ponatinib tabs 08.01.05 Formulary NICE TA451: Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia
Prasugrel tabs 02.09 Formulary NICE TA317: Prasugrel with PCI for ACS (review of TA182)
Prucalopride tablets 01.06.07 Formulary NICE TA211: Constipation (women) - prucalopride
Raloxifene tabs 06.04.01.01 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Raloxifene tabs 06.04.01.01 Formulary NICE TA160: Alendronate, etidronate, risedronate, raloxifene and strontium ranelate for the primary prevention of osteoporotic fragility fractures in postmenopausal women
Ranibizumab intravitreal injection 11.08.02 Formulary NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Ranibizumab intravitreal injection 11.08.02 Formulary NICE TA274: Macular oedema (diabetic) - ranibizumab
Ranibizumab intravitreal injection 11.08.02 Formulary NICE TA298: Choroidal neovascularisation (pathological myopia) - ranibizumab
Ranibizumab intravitreal injection 11.08.02 Formulary NICE TA283: Macular oedema (retinal vein occlusion) - ranibizumab: guidance
Regorafenib tabs 08.01.05 Formulary NICE TA488: Regorafenib for previously treated unresectable or metastatic gastrointestinal stromal tumours
Reslizumab injection 03.04.02 Formulary NICE TA479: Reslizumab for treating severe eosinophilic asthma
Ribavirin 05.03.05 Non Formulary NICE TA300: Hepatitis C (children and young people) - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA106: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA200: Hepatitis C - peginterferon alfa and ribavirin
Ribavirin 05.03.05 Non Formulary NICE TA75: Hepatitis C - pegylated interferons, ribavirin and alfa interferon
Ribavirin caps, tabs 05.03.03.02 Formulary NICE TA75: Interferon alfa (pegylated and non-pegylated) and ribavirin for the treatment of chronic hepatitis C
Ribavirin caps, tabs 05.03.03.02 Formulary NICE TA200: Peginterferon alfa and ribavirin for the treatment of chronic hepatitis C
Ribavirin caps, tabs 05.03.03.02 Formulary NICE TA106: Peginterferon alfa and ribavirin for the treatment of mild chronic hepatitis C
Ribociclib tabs 08.01.05 Formulary NICE TA496: Ribociclib with an aromatase inhibitor for previously untreated, hormone receptor-positive, HER2-negative, locally advanced or metastatic breast cancer
Rifaximin tabs 05.01.07 Formulary NICE TA337: Rifaximin for preventing episodes of overt hepatic encephalopathy
Riluzole tabs 04.09.03 Formulary NICE TA20: Guidance on the use of Riluzole (Rilutek) for the treatment of Motor Neurone Disease
Rituximab injection 10.01.03 Formulary NICE TA195: Rheumatoid arthritis - drugs for treatment after failure of a TNF inhibitor
Rituximab injection 08.02.03 Formulary NICE TA193: Rituximab for the treatment of relapsed or refractory chronic lymphocytic leukaemia
Rituximab injection 08.02.03 Formulary NICE TA137: Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin’s lymphoma
Rituximab injection 08.02.03 Formulary NICE TA174: Rituximab for the first-line treatment of chronic lymphocytic leukaemia
Rituximab injection 08.02.03 Formulary NICE TA226: Rituximab for the first-line maintenance treatment of follicular non-Hodgkin’s lymphoma
Rituximab injection 08.02.03 Formulary NICE TA243: Rituximab for the first-line treatment of stage III-IV follicular lymphoma
Rituximab injection 10.01.03 Formulary NICE TA308: Rituximab in combination with glucocorticoids for treating anti-neutrophil cytoplasmic antibody-associated vasculitis
Rivaroxaban tabs 02.08.02 Formulary NICE TA261: Rivaroxaban for the treatment of DVT and prevention of recurrent DVT and/or PE
Rivaroxaban tabs 02.08.02 Formulary NICE TA256: Rivaroxaban for thromboprophylaxis in AF
Rivaroxaban tabs 02.08.02 Formulary NICE TA287: Rivaroxaban for treating PE and preventing recurrent VTE
Rivaroxaban tabs 02.08.02 Formulary NICE TA335: Rivaroxaban for preventing adverse outcomes after acute management of ACS
Roflumilast tablets 03.03.03 Formulary NICE TA461: Roflumilast for treating chronic obstructive pulmonary disease
Romiplostim injection 09.01.04 Restricted Use NICE TA221: Thrombocytopenic purpura - romiplostim
Ruxolitinib tabs 08.01.05 Formulary NICE TA386: Ruxolitinib for treating disease-related splenomegaly or symptoms in adults with myelofibrosis
Sacubitril and valsartan tabs 02.05.05 Restricted Use NICE TA388: Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction
Sarilumab pre-filled pen or syringe 10.01.03 Formulary NICE TA485: Sarilumab for moderate to severe rheumatoid arthritis
Secukinumab injection 13.05.03 Formulary NICE TA350: Secukinumab for treating moderate to severe plaque psoriasis
Secukinumab injection 10.01.03 Formulary NICE TA407: Secukinumab for active ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors
Secukinumab injection 10.01.03 Formulary NICE TA445: Certolizumab pegol and secukinumab for treating active psoriatic arthritis after inadequate response to DMARDs
Simeprevir caps 05.03.03.02 Formulary NICE TA331: Simeprevir in combination with peginterferon alfa and ribavirin for treating genotypes 1 and 4 chronic hepatitis C
Sirolimus tabs, oral solution 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Sirolimus tabs, oral solution 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Sofosbuvir tabs 05.03.03.02 Formulary NICE TA330: Sofosbuvir for treating chronic hepatitis C
Somatropin injection 06.05.01 Formulary NICE TA64: Growth hormone deficiency (adults) - human growth hormone
Somatropin injection 06.05.01 Formulary NICE TA188: Human growth hormone (somatropin) for the treatment of growth failure in children (review)
Sorafenib 08.01.05 Non Formulary NICE TA189: Hepatocellular carcinoma (advanced and metastatic) - sorafenib (first line)
Sorafenib tablets 08.01.05 Formulary NICE TA474: Sorafenib for treating advanced hepatocellular carcinoma
Sorafenib tablets 08.01.05 Formulary NICE TA535: Lenvatinib and sorafenib for treating differentiated thyroid cancer after radioactive iodine
Spironolactone tabs 02.02.03 Formulary NICE NG106: Chronic heart failure in adults: diagnosis and management
Spironolactone tabs 02.02.03 Formulary NICE CG127: Hypertension in adults: diagnosis and management
Sunitinib caps 08.01.05 Formulary NICE TA169: Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma
Sunitinib caps 08.01.05 Formulary NICE TA179: Sunitinib for the treatment of gastrointestinal stromal tumours
Sunitinib caps 08.01.05 Formulary NICE TA449: Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease
Tacrolimus m/r caps, injection 08.02.02 Formulary NICE TA481: Immunosuppressive therapy for kidney transplant in adults
Tacrolimus m/r caps, injection 08.02.02 Formulary NICE TA482: Immunosuppressive therapy for kidney transplant in children and young people
Tacrolimus ointment 0.03%, 0.1% 13.05.03 Formulary NICE TA82: Tacrolimus and pimecrolimus for atopic eczema
Tegafur with Uracil 08.01.03 Non Formulary NICE TA61: Capcitabine and tegafur - Colorectal cancer
Temozolomide caps 08.01.05 Formulary NICE TA23: Guidance on the use of temozolomide for the treatment of recurrent malignant glioma (brain cancer)
Temozolomide caps 08.01.05 Formulary NICE TA121: Carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma
Tenofovir disoproxil tabs 05.03.01 Formulary NICE CG165: Hepatitis B (chronic) - incorporates TA173
Tenofovir disoproxil tabs 05.03.01 Formulary NICE TA173: Hepatitis B (chronic) - tenofovir disoproxil
Tenofovir disoproxil tabs 05.03.03.01 Formulary NICE TA173: Tenofovir disoproxil for the treatment of chronic hepatitis B
Teriflunomide tablets 08.02.04 Formulary NICE TA303: Teriflunomide for treating relapsing–remitting multiple sclerosis
Teriparatide injection 06.06.01 Formulary NICE TA161: Alendronate, etidronate, risedronate, raloxifene, strontium ranelate and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Tetracycline tabs 05.01.03 Formulary NICE CG184: Gastro-oesophageal reflux disease and dyspepsia in adults: investigation and management
Thalidomide caps 08.02.04 Formulary NICE TA228: Bortezomib and thalidomide for the first‑line treatment of multiple myeloma
Ticagrelor tabs, orodispersible tabs 02.09 Formulary NICE TA236: Acute coronary syndromes - ticagrelor
Ticagrelor tabs, orodispersible tabs 02.09 Formulary NICE TA420: Ticagrelor for preventing atherothrombotic events after myocardial infarction
Tivozanib caps 08.01.05 Formulary NICE TA512: Tivozanib for treating advanced renal cell carcinoma
Tobramycin dry powder for inhalation 05.01.04 Formulary NICE TA276: Colistimethate sodium and tobramycin dry powders for inhalation for treating pseudomonas lung infection in cystic fibrosis
Tocilizumab injection 10.01.03 Formulary NICE TA373: Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis
Tocilizumab injection 10.01.03 Formulary NICE TA247: Rheumatoid arthritis - tocilizumab (rapid review TA198)
Tocilizumab injection 10.01.03 Formulary NICE TA238: Arthritis (juvenile idiopathic, systemic) - tocilizumab
Tocilizumab injection 10.01.03 Formulary NICE TA375: Adalimumab, etanercept, infliximab, certolizumab pegol, golimumab, tocilizumab and abatacept for rheumatoid arthritis not previously treated with DMARDs or after conventional DMARDs only have failed
Tocilizumab subcutaneous injection 10.01.03 Formulary NICE TA518: Tocilizumab for treating giant cell arteritis
Tofacitinib tabs 10.01.03 Formulary NICE TA480: Tofacitinib for moderate to severe rheumatoid arthritis
Tofacitinib tabs 10.01.03 Formulary NICE TA543: Tofacitinib for treating active psoriatic arthritis after inadequate response to DMARDs
Tolvaptan tabs 06.05.02 Restricted Use NICE TA358:Tolvaptan for treating autosomal dominant polycystic kidney disease
Topotecan injection 08.01.05 Formulary NICE TA183: Topotecan for the treatment of recurrent and stage IVB cervical cancer
Topotecan injection 08.01.05 Formulary NICE TA184: Topotecan for the treatment of relapsed small-cell lung cancer
Trabectedin injection 08.01.05 Formulary NICE TA185: Trabectedin for the treatment of advanced soft tissue sarcoma
Trametinib tabs 08.01.05 Formulary NICE TA396: Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma
Trastuzumab emtansine 08.01.05 Non Formulary NICE TA235: Osteosarcoma - mifamurtide
Trastuzumab emtansine injection 08.01.05 Formulary NICE TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane
Trastuzumab injection 08.01.05 Formulary NICE TA107: Trastuzumab for the adjuvant treatment of early-stage HER2-positive breast cancer
Trastuzumab injection 08.01.05 Formulary NICE TA34: Guidance on the use of trastuzumab for the treatment of advanced breast cancer
Trastuzumab injection 08.01.05 Formulary NICE TA208: Trastuzumab for the treatment of HER2-positive metastatic gastric cancer
Trifluridine–tipiracil tablets 08.01.03 Formulary NICE TA405: Trifluridine–tipiracil for previously treated metastatic colorectal cancer
Ustekinumab 13.05.03 Non Formulary NICE TA180: Psoriasis - ustekinumab
Ustekinumab 13.05.03 Non Formulary NICE TA313: Ustekinumab for treating active psoriatic arthritis
Ustekinumab injection 13.05.03 Formulary NICE TA180: Ustekinumab for the treatment of adults with moderate to severe psoriasis
Ustekinumab injection 10.01.03 Formulary NICE TA340: Ustekinumab for treating active psoriatic arthritis
Ustekinumab injection 01.05.03 Formulary NICE TA456: Ustekinumab for moderately to severely active Crohn’s disease after previous treatment
Varenicline tabs 04.10.02 Formulary NICE TA123: Varenicline
Vedolizumab injection 01.05.03 Formulary NICE TA342 Vedolizumab for treating moderately to severely active ulcerative colitis
Vedolizumab injection 01.05.03 Formulary NICE TA352 Vedolizumab for treating moderately to severely active Crohn’s disease after prior therapy
Vemurafenib tabs 08.01.05 Formulary NICE TA269: Vemurafenib for treating locally advanced or metastatic BRAF V600 mutation‑positive malignant melanoma
Venetoclax tabs 08.01.01 Formulary NICE TA487: Venetoclax for treating chronic lymphocytic leukaemia
Verteporfin injection 11.08.02 Formulary NICE NG82: Age-related macular degeneration
Viekirax® 05.03.03.02 Formulary NICE TA 365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
Vinflunine 08.01.04 Non Formulary NICE TA272: Urothelial tract carcinoma (transitional cell, advanced, metastatic) - vinflunine
Vinorelbine caps, injection 08.01.04 Formulary NICE CG121: Lung cancer: diagnosis and management
Vinorelbine caps, injection 08.01.04 Formulary NICE CG81: Advanced breast cancer: diagnosis and treatment
Vismodegib caps 08.01.05 Non Formulary NICE TA489: Vismodegib for treating basal cell carcinoma
Vortioxetine tabs 04.03.04 Formulary NICE CG367: Vortioxetine for treating major depressive episodes
Zepatier® tabs 05.03.03.02 Formulary NICE TA413: Elbasvir–grazoprevir for treating chronic hepatitis C
South East London Joint Medicines Formulary